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The benefit of carotid endarterectomy (CEA) for
patients who were asymptomatic with >60% stenosis
has been established by a controlled clinical trial.1
Detection of asymptomatic lesions requires screen-
ing of patients, usually by duplex ultrasound. Which
screening strategy is most appropriate is unclear. The
cost-effectiveness of screening for asymptomatic
carotid stenosis has become a subject of debate.1-4
We sought to determine the cost-effectiveness of
screening for asymptomatic carotid stenosis by
examining the effect of various variables on quality-
adjusted life years (QALY) and lifetime cost of care.
METHODS
A decision model was developed to examine the
effect of screening or not screening on QALY and
cost. The model combined published data of the
accuracy and cost of duplex Doppler ultrasound and
carotid arteriography and of the risks, benefits, and
costs of endarterectomy to model survival, QALY,
and cost for a hypothetical population. Predicted
QALY and cost for the two choices (ultrasound
screening or no screening, with or without preoper-
ative arteriography) were compared to calculate the
cost-effectiveness ratio (CE-ratio). All calculations
were performed with Decision Maker software
(Decision Maker 7.04, Pratt Medical Group, Inc.,
Massachusetts).
The model
Events in the first month after the decision to
screen are described in Fig. 1. Patients who undergo
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screening are found to have significant asympto-
matic carotid stenosis >60% as defined by the
Asymptomatic Carotid Atherosclerosis Study
(ACAS),1 or they are found not to have significant
stenosis. Ultrasound scans classify patients into the
following two groups: those with a positive test
result (>60% stenosis) and those with a negative test
result (<60% stenosis). Patients with positive tests
undergo arteriography to confirm ultrasound find-
ings. At present, patients with negative test results
do not undergo further testing.
Patients who undergo arteriography may have
periprocedure strokes, which can be minor, major,
or fatal strokes. Patients undergo endarterectomy
when >60% stenosis is verified arteriographically.
The patients may have uncomplicated endarterec-
tomies or complications that result in minor, major
(causing functional deficits persisting >90 days), or
fatal strokes. Presently, patients do not undergo fur-
ther testing without >60% stenosis verified angio-
graphically. Arteriography was assumed to be perfect
in sensitivity and specificity.
Fig. 2 describes a Markov process in the months
after screening. Patients who are aging may move
from one of the eight Markov states to another
(Table I). Patients who are Well may develop asymp-
tomatic (Asym) or symptomatic (Sym) stenoses or
die of unrelated causes. The transitional probability,
the probability of changing from one state to anoth-
er, may change monthly because of time-dependent
effects, such as aging.
Testing and treatment of patients who were
symptomatic. Because transient ischemic attack and
other symptoms are easily recognized by clinicians, we
assumed that patients underwent duplex ultrasound
when symptoms occurred. Patients who were symp-
tomatic with >60% stenosis underwent endarterec-
tomy immediately.5
Follow-up testing. Patients who were sympto-
matic with <60% stenosis and patients who were
postoperative underwent periodic testing. The inter-
val between follow-up tests was assumed to be con-
stant. The interval was every year for the base-case.
Frequency of screening. Different screening
strategies were modeled. A one-time screening
model tested patients who were asymptomatic once
unless they became symptomatic (base-case). Other
screening strategies tested patients periodically.
Death from other causes. The mortality rate
increases with age in the general population.
Patients with cerebrovascular disease have a higher
risk of death than patients who are matched for age.
An excess mortality rate was assessed to account for
this higher risk.
Arteriography versus no arteriography. Because
many clinicians perform endarterectomy without
arteriography to avoid the attendant risk of complica-
tions,6-9 we developed a separate model to study the
cost-effectiveness of screening without arteriography.
This model accounted for the implications of false-
positive and false-negative ultrasound findings.
Transition among states. Patients in one state,
excluding the state of Death, may progress to anoth-
er state from month to month (Fig. 2). Patients in
the Well state could progress to Asym or Sym,
remain Well, or die. Patients in the Asym state could
progress to Sym, have a minor or major stroke, or
die. Patients who are Sym could not progress to the
Well or Asym states.
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Fig. 1. Decision tree of events in month after decision to
screen. Square nodes represent decisions, and circular
nodes are chance nodes. Model accounts for complications
of arteriography and fate of patients who had false-positive
ultrasound scans. Patients enter Markov process after deci-
sion to screen (Fig. 2). Angio, carotid arteriography;
Comp, complications; Dz, patient has 60% to 99% asymp-
tomatic carotid stenosis; Surg, carotid endarterectomy.
Table I. Definition Of Markov States
State Definition
Well Patients with 0% to 59% asymptomatic stenosis
as defined by ACAS
Asym Patients with 60% to 99% asymptomatic carotid
stenosis
Sym Patients who have had a hemispheric transient
ischemic attack or monocular blindness of
<24 hours duration but with stenosis <60%
AsymSurg Patients who have had uncomplicated carotid
endarterectomy for asymptomatic stenosis >60%
SymSurg Patients who have had uncomplicated carotid
endarterectomy for symptomatic stenosis >60%
MinStk Patients who have had minor strokes
MajStk Patients who have had major stroke (e.g., causing
a functional deficit persisting 90 or more days) 
Death Deceased
Data sources
Accuracy of duplex Doppler ultrasound.
Reports of accuracy are highly variable (Table II).10-
14 A metaanalysis estimated that the sensitivity and
specificity of ultrasound ranged from 83% to 86%
and from 89% to 94%, respectively.12 The sensitivity
and specificity were assumed to be 85% and 92%,
respectively, for the base-case analysis.
Disease prevalence. A summary of disease
prevalence is found in Derdeyn et al.2 Several addi-
tional studies merit discussion. In the Framingham
Study, Fine-Edelstein et al.15 found that the preva-
lence of >50% stenosis in patients aged 66 to 93
years was 7% in women and 9% in men. Salonen et
al.16 reported a 4.8% prevalence of >20% stenosis in
Eastern Finnish men aged 60 years. Jungquist et
al.17 also reported a 3% rate of 60% to 99% stenosis
in a Swedish population. In patients who were
referred to the vascular laboratory at the University
of Washington for carotid stenosis evaluation, 14%
had mild cervical bruits, and 114 (8%) had >50%
stenosis.18 We therefore assumed a 5% disease preva-
lence for the base-case analysis (range, 3% to 20%).
Surgical risk. The risks of endarterectomy
include minor and major perioperative (within 30
days) strokes and death during surgery. Base-case
estimates were derived from ACAS results (Table
III).1 The risk of arteriography was excluded. Base-
case estimates for patients who were symptomatic
were taken from the North American Symptomatic
Carotid Endarterectomy Trial (NASCET).5
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Fig. 2. A, Markov model for fate of patients after screening. Well, Asym, Sym, AsymSurg, SymSurg,
MinStk, MajStk, and Death are Markov states (Table I). Patients who are aging may move from one
of eight Markov states to another (i.e., from Well to Asym). B, Markov model for monthly transition
for patients who develop asymptomatic stenosis after screening has been completed. Patients may have
stroke, remain asymptomatic, or develop symptoms. Those developing symptoms (i.e., transient
ischemic attack) are assumed to undergo ultrasound testing and then arteriographic verification and
endarterectomy in patients with confirmed 60% to 99% stenosis. Square nodes represent decisions and
circular nodes are chance nodes. Angio, carotid arteriography; Comp, complications; Dz, 60% to 99%
stenosis; Surg, Carotid endarterectomy.
Table II. Accuracy of duplex ultrasound
Authors No. of cases Sensitivity Specificity Notes
Eliasziw et al.10 1011 0.68 0.67 Symptomatic patients with ‡ 70% stenosis
Moneta et al.11 353 0.84 0.94 60% to 99% asymptomatic carotid artery stenosis
Blakeley et al.12 3574 0.83-0.86 0.89-0.94 Meta-analysis, published articles; 70% to 99% stenosis
Kent et al.13 81 0.35-0.93 0.78-0.96 70% to 99% stenosis in symptomatic patients
Derdeyn et al.2 215 0.99 0.80 60% to 99% stenosis
Carpenter et al.14 110 0.97-1.0 0.52-1.0 60% to 99% stenosis
Stroke risk. The estimated monthly rate of
stroke in patients who were asymptomatic was
derived from ACAS results.1 The risk of perioperative
strokes was excluded. In the ACAS study, the month-
ly rate of ipsilateral stroke, excluding perioperative
stroke, was 0.05% (-LN(1-(0.051-0.023))/60 =
0.05%) for patients for surgical treatment and 0.19%
(-LN(1-(0.11-0.004))/60 = 0.19%) for patients for
medical treatment, with a relative risk reduction of
75%. The monthly rate of any stroke was 0.20% for
patients for surgical treatment and 0.33% for patients
for medical treatment, with a relative risk reduction
of 41%. Because we did not separate ipsilateral stroke
from other types of stroke, we used the rate of any
stroke as our base-case estimate for stroke risk. We
chose the more conservative, or less likely to be cost-
effective, rate of any stroke, rather than ipsilateral
stroke, because we were interested in determining
overall benefit to patients and costs.
The stroke rate for patients who were sympto-
matic was taken from NASCET results (Table IV).5
The monthly rate of any stroke, excluding perioper-
ative stroke, was 0.58% for patients for surgical treat-
ment and 1.4% for patients for medical treatment,
with a relative risk reduction of 59%. The European
Carotid Surgery Trial found no benefit from surgery
in patients who were symptomatic with <30% steno-
sis.19 NASCET and the European Carotid Surgery
Trial have not reached definitive conclusions about
patients who are symptomatic with stenosis between
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Fig. 3. Solid line shows prevalence of disease in screening
population and cost-effectiveness of screening. Screening
was cost-effective if prevalence of asymptomatic carotid
stenosis was more than 4.5%. Dashed line shows surgical
efficacy for patients who were asymptomatic and cost-
effectiveness of screening. Screening was cost-effective if
surgical efficacy was more than 37%. Surgical efficacy, (rate
of stroke in medical patients - rate of stroke in surgical
patients)/(rate of stroke in medical patients); CE-Ratio,
Cost/QALY = (cost of screening - cost of not screen-
ing)/(QALY of screening - QALY of not screening).
Table III. Perioperative risks
Procedure Mortality Nonfatal
(sources) rate complication rate
Angiography (ACAS)1 1/414 (0.24%) 4/414 (0.97%)
Carotid endarterectomy 2/825 (0.24%) 11/825 (1.33%)
for asymptomatic
patients (ACAS)1
Carotid endarterectomy 2/328 (0.61%) 17/328 (5.18%)
for symptomatic
patients (NASCET)5
ACAS, Asymptomatic Carotid Atherosclerosis Study1; NASCET,
North American Symptomatic Carotid Endarterectomy Trial.5
The rate of surgical complications for asymptomatic patients does
not include the risk of carotid arteriography related complica-
tions.
Table IV. Annual stroke rate after the perioperative
period
Relative
risk 
Event type (source) Medical Surgical reduction 
Any ipsilateral stroke in patients 2.28% 0.72% 75%
with asymptomatic 60% to 99%
stenosis (ACAS)1
Any stroke in patients with 3.96% 2.4% 41%
asymptomatic 60% to 99%
stenosis (ACAS)1
Any ipsilateral stroke in patients 12.84% 1.68% 87%
with symptomatic 70% to 99%
stenosis (NASCET)5
Any stroke in patients with 16.8% 6.96% 59%
symptomatic 70% to 99%
stenosis (NASCET)5
ACAS, Asymptomatic Carotid Atherosclerosis Study1; NASCET,
North American Symptomatic Carotid Endarterectomy Trial5;
Relative risk reduction, (rate of stroke in medical patients - rate of
stroke in surgical patients)/(rate of stroke in medical patients).
The rate of stroke does not include perioperative (within 30 days)
strokes.
30% and 69%, and both trials continue to randomize
such patients. We assumed that patients who were
symptomatic with 60% to 99% stenosis underwent
endarterectomy immediately, and those patients
with <60% symptomatic stenosis were medically
managed. The risk of stroke in patients who were
medically treated and symptomatic with <60% symp-
tomatic stenosis was assumed to be 50% of those
patients with 70% to 99% stenosis (0.5 · 1.4% =
0.7% from NASCET). In NASCET, 49% of postop-
erative strokes in patients for medical treatment were
major, and 18% of the major strokes were fatal.
Patients with a stroke have a 5% to 9% annual
rate of subsequent stroke and a monthly rate of 0.4%
to 0.8%.20 A monthly rate of 0.8% was used for the
base-case analysis.
Excess mortality rate. An excess mortality rate
was calculated as the difference between the
NASCET’s rate of nonstroke death in patients for
medical treatment and the actuarial rate of death in
the general population.21 The excess mortality rate
for patients who were surgical and asymptomatic
(60% to 99% stenosis) was assumed to be the same
for patients who were symptomatic. The excess mor-
tality rate for patients with minor and major strokes
was assumed to be 200% and 500%, respectively, of
the rate in patients who were symptomatic.
Transitional probability. The monthly transi-
tional probability from asymptomatic to sympto-
matic with >60% carotid stenosis was estimated from
ACAS results. The monthly rate was 0.19% in
patients for medical treatment and 0.08% in patients
for surgical treatment. The transitional probability
from Well to Asym (from asymptomatic <60% steno-
sis to asymptomatic >60% stenosis) was extrapolated
from the literature. Salonen et al.16 found that 4.8%
of 60-year-old patients had >20% stenosis as com-
pared with 2.3% in 54-year-old patients. This result
implies a monthly transition rate of 0.4%. The rate
was 0.45% for a similar method that was applied to
the Framingham Study results.15 The rate of transi-
tion from the Well to the Sym state (from <60%
asymptomatic stenosis to symptomatic >60% steno-
sis) was assumed to be 50% of that from Well to
Asym (0.4% · 0.5 = 0.2%).
Quality of life adjustment and discounting.
The degree to which major and minor strokes
diminish the quality of life for a patient was adjusted
with a factor that ranged from zero (Death) to one
(Well). Our adjustment factors were derived from
earlier studies.22,23 Future expenditures and QALY
were discounted at an annual discount rate of 5% but
were tested at a range of 0% to 10%.
Costs. The cost of ultrasound was taken from
the Medicare fee schedule. Costs of arteriography
and endarterectomy were from Kent et al.13 The fol-
lowing costs were derived: ultrasound, $206; arteri-
ography, $2360; and endarterectomy, $10,850. We
also followed Kent et al.13 by adding a one-time cost
of $13,000 for each minor or fatal stroke and
$27,000 for each major stroke. These costs reflect
estimated fees per patient who is hospitalized for
stroke. In addition, we assumed that patients with
minor and major strokes incurred $120 and
$12,000 annually for chronic care, respectively. All
costs are in 1994 United States dollars.
Table V summarizes these assumptions. Our
base-case results apply to the decision to screen by
ultrasound a population of 60-year-old patients who
are asymptomatic and have a 5% prevalence of 60%
to 99% asymptomatic stenosis.
RESULTS
Base-case analysis. Table VI reports costs and
QALY of screening versus not screening under base-
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Fig. 4. Surgical complications and cost-effectiveness of
screening. Screening was cost-effective if surgical compli-
cation rate was less than 160% of that in ACAS and
NASCET. Surgical complications, rate of surgical compli-
cations compared with rates of complications in ACAS (for
asymptomatic patients) and NASCET (for symptomatic
patients); CE-Ratio, Cost/QALY = (cost of screening -
cost of not screening )/(QALY of screening - QALY of
not screening).
case assumptions. The screening of the hypothetical
population increased average QALY (11.485 vs
11.473) and lifetime cost ($5500 vs $5013; Table
VI, first three rows). The incremental cost was
$39,495 per QALY gained.
If endarterectomy was performed on the basis of
ultrasound results alone (Table VI, last three rows),
screening as compared with not screening increased
QALY (11.486 vs 11.473) and cost ($6896 vs
$5589). The CE-ratio was $100,508. When the two
screening strategies (with and without arteriogra-
phy) were compared, screening without arteriogra-
phy provided few QALYs (11.486 vs 11.485) at a
cost of $1390 ($6896 vs $5500) resulting in a CE-
ratio of $1,396,000.
Sensitivity analysis. Each variable in Table V
was examined to determine the effect on the CE-
ratio. Fig. 3 through Fig. 8 illustrate relationships
between CE-ratio and selected parameters. The last
column of Table V summarizes the effect of each
variable on the cost-effectiveness of screening.
Disease prevalence. Screening was more cost-
effective (CE-ratio was lower) in patients with
greater disease prevalence (Fig. 3). As prevalence
increased from 3% to 20%, the CE-ratio decreased
from $102,160 to $7452. If we accept the current
standard that a CE-ratio of $50,000 or less suggests
an intervention is cost-effective, threshold preva-
lence was 4.5% for screening to be cost-effective
(Table V, last column). Although no consensus on
the exact limits of acceptable CE-ratios exists, inter-
ventions with CE-ratios of $50,000 or less are often
considered cost-effective when compared with cur-
rently acceptable medical practices. Interventions
with CE-ratios between $50,000 and $100,000 are
considered borderline cost-effective, and those with
higher ratios are not cost-effective.24
Surgical efficacy. The CE-ratio ranged from
$357,869 to $6023 and surgical efficacy in patients
who were asymptomatic varied from 20% to 80% rel-
ative risk reduction (Fig. 3). The threshold efficacy
was 37%. Surgical efficacy for patients who were
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Fig. 5. Sensitivity and specificity of ultrasound and cost-
effectiveness of screening. Cost-effectiveness of screening
was independent of sensitivity of ultrasound (dashed line).
Screening was cost-effective if specificity of ultrasound was
more than 91% (solid line). CE-Ratio, Cost/QALY = (cost
of screening - cost of not screening )/(QALY of screening -
QALY of not screening).
Fig. 6. Annual rate of strokes in patients with 60% to 99%
asymptomatic stenosis and cost-effectiveness of screening.
Screening was cost-effective if stroke rate of patients who
were medically managed and asymptomatic was more than
3.3%. CE-Ratio, Cost/QALY = (cost of screening - cost
of not screening)/(QALY of screening - QALY of not
screening).
symptomatic did not affect the cost-effectiveness of
screening.
Surgical complications. Both ACAS and
NASCET selected surgeons by strict quality criteria
to minimize the perioperative risks of endarterecto-
my (Fig. 4). We varied complication rates to exam-
ine the cost-effectiveness of screening when
endarterectomy was performed in various clinical
settings. If the complication rate was twice the
ACAS and NASCET rates, the CE-ratio was
$58,251. If the rate was reduced to half of the base-
case rate, the CE-ratio was $33,575. Screening was
cost-effective if the rate was less than 160% of that of
ACAS and NASCET.
Accuracy of screening. The CE-ratio varied
with the accuracy of screening (Fig. 5). As the speci-
ficity of ultrasound varied from 83% to 99%, the CE-
ratio ranged from $208,470 to $13,050. The
threshold specificity was 91%. The sensitivity of
ultrasound had smaller effects on the CE-ratio,
which ranged from $44,019 to $29,819 as sensitiv-
ity increased from 80% to 90%. Screening without
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Table V. Model parameters: base-case value, range, and effect on CE-ratio
Base-case CE-ratio
Variable (sources) (Range) <$50,000?
Prevalence of 60-99% carotid stenosis2,15-17 5% (3% to 20%) If >4.5%
Sensitivity of screening test10-14 0.85 (0.8-0.99) Any*
Specificity of screening test10-14 0.92 (0.8-0.99) If >0.91
Starting age of screening 60 (55-75) If <63
Frequency of screening Once (every 1-10 years) If once
Interval between postoperative follow-up tests (months)27 12 (6-60) Any*
Interval between follow-up tests for symptomatic patients (months) 12 (6-60) Any*
Annual stroke rate in asymptomatic patients1 3.96 (0-7.92) If >0.28% 
Annual stroke rate in patients with <60% symptomatic stenosis5 8.4 (4.2-16.8) Any*
Annual stroke rate in patients who have had minor strokes20 9.6 (0-28.8) Any*
Annual stroke rate in patients who have had major strokes20 9.6 (0-28.8) Any*
% of strokes that are major1,5 50% (25% to 75%) If >42%
% of major strokes that are fatal1,5 18% (10% to 50%) Any*
Rate of arteriography-related strokes1 1.2% (0% to 1.5%) If <1.4%
% of arteriography-related strokes that are fatal 10% (0% to 30%) Any*
% of arteriography-related strokes that are major strokes 30% (0% to 60%) If <51%
Efficacy in patients with 60% to 99% asymptomatic stenosis1 41% (20% to 82%) If >37%
Perioperative mortality rate in asymptomatic patients1 0.24% (0.12% to 0.48%) If <160%†
Perioperative major stroke rate in asymptomatic patients1 0.38% (0.19% to 0.76%) If <160%†
Perioperative minor stroke rate in asymptomatic patients1 0.92% (0.46% to 1.84%) If <160%†
Efficacy of endarterectomy in asymptomatic patients1 59% (30% to 80%) Any*
Perioperative mortality rate in symptomatic patients5 0.6% (0.3% to 1.2%) If <160%†
Perioperative major stroke rate in symptomatic patients1 1.5% (0.75% to 3%) If <160%†
Perioperative minor stroke rate in symptomatic patients1 3.7% (1.35% to 7.4%) If <160%†
% of stenoses that are 70% or greater in patients with symptomatic stenosis 48% (24% to 96%) Any*
Transition probability from Well to Asym5,15,16 0.04% (0% to 0.12%) Any*
Transition probability from Well to Sym (see text) 0.02% (0% to 0.06%) Any*
Transition probability from Asym to Sym1 0.19% (0% to 0.38%) If >0.15%
Transition probability from AsymSurg/SymSurg to Sym1 0.08% (0% to 0.16%) If <0.12%
Excess annual mortality rate5 2.28 (0-0.0456) Any*
Excess annual mortality rate in patients with minor strokes 0.0456 (0-0.0912) Any*
Excess annual mortality rate in patients with major strokes 0.114 (0-0.228) Any*
Quality of life for minor stroke patients 0.8 (0.5-1.0) Any*
Quality of life for major stroke patients 0.2 (0-0.5) If <0.44
Annual discount rate 5% (0% to 10%) If <7%
Cost of ultrasound $206 (100-800) If <$300
Cost of carotid endarterectomy13 $10,850 ($5,000-$20,000) If <$18,000
Cost of carotid arteriography13 $2,360 ($1,000-$4,000) If <$3,400
Cost of chronic care for major stroke (annual rate) $12,000 ($6000-$24,000) Any*
Duration of surgical efficacy (years) 10 (5-12) If >8 years
Efficacy, (1-(rate of strokes in surgical patients)/(rate of strokes in medical patients)); CE-ratio, (cost of screening - cost of not screen-
ing)/(quality-adjusted life-year of screening - quality-adjusted life-year of not screening).
*The CE-ratio remained less than $50,000 when the corresponding parameter was varied within its range.
†The rate of surgical complications was compared with the rates in ACAS and NASCET (the base-case). A ratio of 100% implied that
the rate of surgical complications in asymptomatic patients was the same as the ACAS rate and the rate in symptomatic patients was the
same as the NASCET rate.
arteriography was cost-effective when compared
with screening with arteriography only if the speci-
ficity of ultrasound was 98% or greater.
Stroke rate. As the annual rate of stroke in
patients who were asymptomatic increased from
1.2% to 7.6%, the CE-ratio decreased from
$198,889 to $19,536 (Fig. 6). Screening was cost-
effective if the annual stroke rate was more than
3.3%.
Cost of screening. The CE-ratio was also sensi-
tive to the cost of ultrasound (Fig. 7). As the cost
increased from $100 to $800, the CE-ratio
increased from $28,291 to $102,277. The threshold
cost was $300.
Arteriography-related complications. The
relationship between the CE-ratio and the rate of
arteriography-related complications is illustrated in
Fig. 8. The CE-ratio was related inversely to the rate
of complications and still remained below $50,000 if
the complication rate was 1.4% or lower.
Other variables. The cost-effectiveness of
screening (CE-ratio < $50,000; Table V, last col-
umn) was sensitive to frequency of screening, patient
age, percentage of major strokes, rate of arteriogra-
phy-related strokes, transitional probability from
asymptomatic to symptomatic, rate of postoperative
symptoms, length of surgical efficacy, discount rate,
cost of surgery and arteriography, and quality of life
in patients with major strokes. The cost-effectiveness
of screening was not sensitive to sensitivity of ultra-
sound, interval between follow-up tests, stroke rate
in patients who are symptomatic, stroke rate in
patients with prior strokes, percentage of fatal major
strokes, surgical efficacy in patients who are sympto-
matic, prevalence of 60% to 99% stenosis in patients
who are symptomatic, transitional probability from
Well to Asym or Sym, excess mortality rate, quality
of life adjustment for patients with minor strokes,
and cost of chronic care for patients with strokes. In
addition, the use of ipsilateral stroke rate, as com-
pared with any stroke, did not significantly change
the cost-effectiveness of screening.
DISCUSSION
Ultrasound screening for asymptomatic carotid
stenosis in a general elderly population can increase
QALY and be cost-effective if ultrasound is specific
and endarterectomy is performed with low morbid-
ity and mortality rates. However, this conclusion is
contingent on the assumptions in the cost-effective-
ness analysis.
First, base-case efficacy and risk of endarterecto-
my were derived from results of controlled clinical
trials, which necessitates that surgery provide more
than 37% relative risk reduction compared with
medical management. The conclusions apply only
when endarterectomy is performed by surgeons who
have comparable results. CEA should be performed
by surgeons with documented morbidity rates less
than 160% of that reported in NASCET, for patients
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Fig. 7. Cost of ultrasound and cost-effectiveness of
screening. Screening was cost-effective if cost of ultra-
sound was less than $300. CE-Ratio, Cost/QALY = (cost
of screening - cost of not screening)/(QALY of screening -
QALY of not screening).
Table VI. Cost and QALY of screening versus not
screening for patients with 5% prevalence of asymp-
tomatic stenosis
Strategy QALY Cost CE-ratio
Carotid arteriography
was performed before
endarterectomy
No screening 11.473 $5,013 N.A.
Screening 11.485 $5,500 $39,495
Endarterectomy
performed on the
basis of ultrasound
results
No screening 11.473 $5,589 N.A.
Screening 11.486 $6,896 $100,538
QALY, quality-adjusted life year; N.A., not applicable; CE-ratio,
(cost of screening - cost of not screening)/(quality-adjusted life
year of screening - quality-adjusted life year of not screening).
who were symptomatic, and ACAS, for patients who
were asymptomatic, and at a cost less than $18,000.
Surgeons therefore would be required to closely
monitor their individual results for operations on
patients who were symptomatic and asymptomatic.
Second, the cost-effectiveness of screening was
sensitive to many variables. Screening was more
cost-effective when performed once in high disease
prevalence populations (>4.5% prevalence). There-
fore a higher priority should be given to testing
patients with cervical bruits, a history of smoking,
diabetes, and high serum cholesterol levels.
Third, our base-case stroke rate was derived from
ACAS, which applied extensive exclusion criteria in
cohort selection. If the stroke rate of patients who
were treated medically is lower than 3.3%, the CE-
ratio would exceed $50,000. We followed Kent et
al.13 with respect to cost of stroke care, but by sensi-
tivity analysis found that screening was cost-effective
over a wide range of assumed costs. We used the rate
of any stroke, rather than only ipsilateral stroke, in
our analysis because we were interested in determin-
ing the overall benefit and cost. This conservative
assumption would disfavor cost-effectiveness of
screening, but screening proved to be cost-effective
over a wide range of stroke rates for medical therapy.
In our model, we chose to vary age and disease
prevalence independently. This artificial separation
of two closely-linked variables was necessary because
of the lack of data needed to accurately assign preva-
lence by age. The data seemed to vary greatly by
author and geographic region. Linking age and
prevalence would likely increase the cost-effective-
ness of screening for asymptomatic stenosis because
increasing values of each variable are associated with
incremental increases in cost-effectiveness when
treated independently.
ACAS noted a more modest relative risk reduc-
tion with surgical treatment of asymptomatic carotid
stenosis for women than for men (17% vs 66%). We
did not examine sex independent of other variables.
However, we did perform sensitivity analysis of sur-
gical relative risk reduction, which may be applied to
the question. The threshold value of cost-effective-
ness for relative risk reduction by surgery was 37%,
which would imply that screening of female patients
may be less likely to be cost-effective. However,
because the model did not specifically address the
issue of sex independently, no firm conclusions can
be made.
The specificity of the screening test should
exceed 91%, and the cost should be less than $300,
which mandates strict quality assurance efforts by
vascular laboratories to assure that such high speci-
ficities of testing can be achieved. The sensitivity of
our model to specificity but not sensitivity of ultra-
sound implies that false-positive ultrasound study
results are of chief importance in cost-effectiveness.
The high cost of unnecessary patient morbidity
incurred by arteriography and operations on patients
without disease is of greater significance than miss-
ing patients with asymptomatic stenosis during
screening.
Confirmatory arteriography should be per-
formed with an attendant morbidity rate less than
1.4%, and the cost should be less than $3400.
Requiring confirmatory arteriography shows the
importance of avoiding unnecessary operations on
patients with false-positive ultrasound results. The
modeled strategy of surgery without preoperative
arteriography was comparable in QALY with the
strategy that required confirmatory arteriography,
but the cost was much higher and exceeded the
amount defined as cost-effective. Once again, the
false-positive ultrasound scans with the attendant
increase in cost because of unnecessary surgery were
chiefly responsible for the effect. The potential ben-
efit of surgery without confirmatory arteriography
was erased by the cost of operations performed on
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Fig. 8. Rate of carotid arteriography-related complica-
tions and cost-effectiveness of screening. Screening was
cost-effective if rate of arteriographic complications was
less than 1.4%. CE-Ratio, Cost/QALY = (cost of screen-
ing - cost of not screening)/(QALY of screening - QALY
of not screening).
patients who did not meet the criteria of the ran-
domized trials. Our model suggests that results of
CEA performed on the basis of duplex alone are
equivalent medically to those obtained when confir-
matory arteriography is required, with QALY nearly
identical. The difference between the two strategies
is confined to cost. Surgeons who perform CEA on
the basis of duplex alone clearly need to rely on val-
idated duplex criteria, which provide high specifici-
ty.25 Perhaps the most sensible strategy would be
one that combines confirmatory arteriography for
stenoses in the low end of the >60% category, where
duplex specificity is lowest. A duplex only strategy
could be used for high grade lesions, which are like-
ly to be nearly all >60%. Such an approach would be
expected to decrease the morbidity rate because of
operations prompted by false-positive duplex study
results and because of arteriographic complications,
while increasing overall cost-effectiveness.
Three recent studies have examined the cost-
effectiveness of screening in patients who are asymp-
tomatic. Derdeyn et al.2 found that screening of a
high-prevalence asymptomatic population (20%
prevalence) led to reduced incidence of stroke.
Matchar et al.4 and Lee et al.26 found that screening
was not cost-effective in patients who are asympto-
matic. Derdeyn et al.2 did not explicitly model the
process of aging and disease progression. Therefore
a comparison of those results with our results is dif-
ficult. The latter studies used similar methods but
arrived at different conclusions. We therefore sought
to determine the causes.
Discrepancies could result from differences in
base-case or model structures. We first modified our
assumptions to resemble those used in Matchar et
al.4 These changes made screening more costly
($4147 vs $3227) and less effective (10.2469 vs
10.2552) than not screening. This change did not
result from any single variable but to simultaneous
changes of the following variables: rate of perioper-
ative mortality and complications, cost of ultra-
sound, patient age, and interval of follow-up tests.
Our base-case estimates of perioperative mortality
rate and complications in patients who were asymp-
tomatic derived from ACAS were much lower than
those used in Matchar et al.4 (0.24% vs 1.5% and
1.33% vs 5%, respectively).
Our model also differed from Matchar et al.4 in
structure. First, our patients underwent tests and
treatment when symptoms occurred. Second,
patients who were symptomatic were given ultra-
sound scans. Third, our Markov model had more
states (eight vs three) so that the process of aging
and disease progression were represented more
accurately.
Lee et al.26 also used different assumptions from
those used in our model. They did not account for
effects of aging, as we did. They also assumed that
CEA conferred no benefit to patients beyond 5 years
whereas we assumed lifelong benefit from CEA.
Like many other cost-effectiveness analyses,
however, we relied on published data from the liter-
ature, which has inherent biases. Published data on
accuracy of ultrasound are subject to verification
biases. The data are often derived from results in
academic medical centers, which are different from
community practices.
Our model also made simplifying assumptions.
Carotid arteriography was assumed to have perfect
sensitivity and specificity, which could have created a
bias in favor of screening. We also assumed that the
interval between follow-up tests was constant (every
year). The effect on the cost-effectiveness of screen-
ing is difficult to assess. We did not account for the
cost of preoperative cardiac or medical evaluation,
which may influence the cost-effectiveness of screen-
ing. We assumed no benefit of CEA performed in
patients with <60% carotid stenosis (false-positives).
This oversimplification could bias against cost-effec-
tiveness of screening. Although the authors are
unaware of documented benefit of CEA for asymp-
tomatic stenosis <60%, presumably carotid
endarterectomy produces a continuum of benefit
rather than none at all.
Finally, our screening strategies were derived
from duplex ultrasound with and without arteriog-
raphy. We did not study magnetic resonance angiog-
raphy as a supplement to ultrasound. The combina-
tion of ultrasound and magnetic resonance angiog-
raphy supplemented by arteriography was found by
Kent et al.13 to provide the most favorable CE-ratio
in evaluating patients who were symptomatic during
hospitalization.
CONCLUSION
Screening of asymptomatic patients for more
than 60% critical stenosis by duplex ultrasound can
increase QALY and can be cost-effective. Both the
screening test and subsequent procedures must be
performed in centers of excellence to achieve these
results.
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